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Abstract 
 
Background 
In the UK, almost 60% of service users diagnosed with schizophrenia say they are not 
involved in decisions about their treatment. Guidelines and policy documents recommend 
that shared decision-making should be implemented, yet whether it leads to greater 
treatment-related empowerment for this group has not been systematically assessed. 
 
Aims 
To examine the effects of shared decision-making on indices of treatment-related 
empowerment of service users with psychosis. 
 
Method 
We conducted a systematic review and meta-analysis of randomised controlled trials of 
shared decision-making for current or future treatment for psychosis (PROSPERO 
registration CRD42013006161). Primary outcomes were indices of treatment-related 
empowerment and objective coercion (compulsory treatment). Secondary outcomes were 
treatment decision-making ability and the quality of the therapeutic relationship. 
 
Results 
We identified 11 randomised controlled trials. Small beneficial effects of increased shared 
decision-making were found on indices of treatment-related empowerment (6 RCTs; g = 
0.30, 95% CI 0.09 to 0.51), although the effect was smaller if trials with >25% missing data 
were excluded. There was a trend towards shared decision-making for future care leading to 
reduced use of compulsory treatment over 15-18 months (3 RCTs; RR 0.59, 95% CI 0.35, 
1.02), with a number needed to treat of approximately 10 (95% CI 5, ∞). No clear effects on 
treatment decision-making ability (3 RCTs) or the quality of the therapeutic relationship (8 
RCTs) were found, but data were heterogeneous.  
 
Conclusions 
For people with psychosis, the implementation of shared treatment decision-making appears 
to have small beneficial effects on indices of treatment-related empowerment, but more 
direct evidence is required. 
 
Declaration of interest 
A.P.M. is a member of two National Institute for Health and Clinical Excellence guideline 
development groups: Psychosis and Schizophrenia in Children and Young People, and 
Psychosis and Schizophrenia in Adults (partial update).  
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Introduction 
 
"The Commission believes that shared decision-making on medication choices is essential to 
improving outcomes…This means practitioners discussing medication options fully with 
service users (and) providing them with quality information so that informed decisions can 
be made."  [The Schizophrenia Commission, 2012; p.30 (1)]   
 
Shared decision-making (SDM) in healthcare has been described as a process of supportive 
collaboration between clients and clinicians, drawing on evidence and the client’s 
preferences and values to reach a consensus about treatment or care. (2, 3) It is seen as 
falling mid-way on a continuum between paternalistic decision-making practices by 
clinicians and autonomous, informed decision-making by clients.(4-7) Whilst a significant 
body of research exists demonstrating the benefits of SDM in physical healthcare,(8) 
research and practice in the area of SDM in relation to people with mental health problems 
is still at a formative stage.(9) SDM may be particularly relevant in psychosis, where 
increasing treatment-related empowerment and reducing use of coercion have been 
identified by service users as outcomes of intrinsic value  (10-13). If clinical trials of SDM 
show it to be effective at improving these outcomes, then this would support existing 
recommendations that SDM be widely implemented with this group. (1, 14)  
 
We conducted a systematic review and meta-analysis of randomised controlled trials of 
SDM in psychosis, with the overall aim of finding out whether enhancing SDM can improve 
treatment-related empowerment in this group, as judged by participants and indicated by 
objective measures. The effect of enhancing SDM on secondary outcomes of quality of 
service user/provider relationship (service user or observer-rated) and decision-making 
abilities and knowledge (clinician-rated) were also evaluated. 
 
Method 
 
Search strategy  
The electronic databases, Medline (1946- ), PsychInfo (1806- ), EMBASE (1980- ), 
CINAHL (1937- ) and The Cochrane Central Register of Controlled Trials (CENTRAL) 
were searched by the DS and MP in August 2013 and January 2015, respectively, along 
with the references of two previous reviews of SDM interventions in mental health care. (4, 
5) Titles, abstracts and keywords were searched using the terms ‘shared decision making’, 
‘psychosis’ and ‘randomised controlled trial’, with related terms in each case. The full 
search strategy is available in the supplementary material. The search was not limited by 
date or publication status, but non-English studies were not included. Initial screening and 
data extraction was carried out by DS, and studies published between 2013 and 2015 were 
screened and extracted by MP. PH provided supervision of screening and extraction, and 
arbitration in the event of uncertainty.  
 
Inclusion and exclusion criteria 
Trials were included if they compared (1) a psychosocial intervention designed to enhance 
SDM in the planning of treatment for psychosis with (2) usual care or a non-specific control 
treatment. SDM was defined as a process of supportive collaboration between clients and 
clinicians, drawing on evidence and the client’s preferences and values to reach a consensus 
about treatment or care (3, 15). Interventions to enhance SDM could be delivered either 
individually or in a group format, and could involve either current or future treatment 
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decisions (ie., joint crisis planning), but they had to share a focus on promoting SDM as 
defined above and they had to involve direct contact with patients or clinicians. Thus, 
studies of advance statements or care planning not involving promotion of SDM were 
excluded, as were studies where interventions were provided to family members or carers. 
We included trials where assessing the effects of promoting SDM was either a primary or 
secondary aim of the study.   
 
Participants 
We included studies where ≥50% of participants had a diagnosis of a schizophrenia-
spectrum disorder. Studies where >50% of participants had a diagnosis of bipolar disorder 
or learning disability; or where psychosis was predominantly substance-induced or organic 
in origin, were excluded. We did not include participants at risk of developing psychosis, 
and we did not exclude participants on the basis of age or stage of established illness. 
 
Outcomes 
Two primary outcomes were chosen: (1) subjective empowerment and (2) reduced objective 
coercion. For the first outcome, a scoping review of the literature suggested that few studies 
measured subjective empowerment directly. Several, however, measured aspects of 
empowerment or closely related concepts. In order to include as many studies as possible, a 
conceptual hierarchy was developed to specify, in advance, the order of preference for the 
data that would be extracted and analysed, based on its closeness to the concept of 
empowerment. The hierarchy was structured as follows: self-reported subjective 
empowerment > treatment decision-making self-efficacy > health-related locus of control > 
patient-perceived involvement in treatment decision-making > patient-centredness of service 
user/provider interaction > reduced perceived coercion. The second primary outcome was 
reduced objective coercion as indicated by fewer admissions under mental health legislation. 
This would be the Mental Health Act (MHA) (2003/2007), where studies had taken place in 
the UK, or corresponding legislation within the country concerned, where studies had taken 
place elsewhere. We originally planned to analyse days spent in hospital under compulsory 
care for this outcome, however skewed or unavailable data meant we decided to analyse 
admission rates instead. Secondary outcomes were quality of service user/provider 
relationship (service user or observer rated) and decision-making abilities and knowledge 
(clinician-rated). For all outcomes, we included data derived from both validated and non-
validated scales, although use of the latter was considered when assessing the quality of the 
individual outcome.  
 
Data extraction 
Summary data (means, standard deviations) were extracted where possible from relevant 
studies using a spreadsheet. Information on study characteristics was also collated. Authors 
were contacted where information was missing. When means and standard deviations were 
not reported and the authors were unable to supply this information, other parameters such 
as F-values, regression coefficients, p-values and sample size were used to estimate the 
standardised mean difference (SMD) using equations specified in the Cochrane 
Handbook.(16) In the absence of available continuous data, proportions were converted to 
SMDs using the Campbell Collaboration’s Practical Meta-Analysis Effect Size Calculator 
(http://www.campbellcollaboration.org/resources/effect_size_input.php). Numbers 
randomised were used where appropriate methods for imputing missing data were reported, 
but limitation to use of n reported for the analysis was expected where this was not the case. 
Missing data was assessed as part of the risk of bias assessment, but no tests of robustness of 
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estimates to changing assumptions around missing data were planned or performed. For the 
binary outcome of compulsory admission, we assumed those randomised but unaccounted 
for had an unchanged outcome from randomisation. 
 
Meta-analytic calculations 
Continuous data were extracted and combined using MetaXL Version 2.0 
(http://www.epigear.com) to derive the SMD and 95% confidence intervals, with Hedge’s g 
employed to adjust for small sample sizes. Statistical significance was inferred with P-
values of <0.05, using two-tailed hypotheses. Analyses employed a random-effects model 
although a fixed-effect analysis was also performed where the I2 statistic indicated less than 
moderate heterogeneity (defined a priori as 40%).(16) Cohen’s proposed criteria for 
interpretation of effect sizes (small = 0.2, moderate = 0.5, large = 0.8) (17) were used in the 
absence of more specific criteria for judging clinical significance of standardised mean 
differences. For the binary outcome of objective coercion (compulsory admission), we 
computed the pooled relative risk of the unfavourable outcome, the risk difference and 
number needed to treat, each with 95% confidence intervals. 
  
Sensitivity analyses 
Sensitivity analyses were used to assess the effect of excluding studies with >25% attrition.  
 
Pre-registration of review protocol 
The review protocol was registered in advance with PROSPERO (International Prospective 
Register of Systematic Reviews).(18)  
 
Risk of bias and study quality 
Risk of bias was assessed for each study using the Cochrane Collaboration Risk of Bias 
Tool.(19) Assessment of outcome quality was performed using the GRADE approach.(20) 
Risk of performance bias was not used as a criterion for downgrading the quality of the 
evidence, since it is essentially unavoidable in trials of psychosocial interventions, and to 
downgrade on this basis was judged to be overly conservative. Risk of publication bias 
using funnel plots was planned if there were sufficient studies (≥10).(21) GRADE ratings 
were used to determine overall confidence in the reliability of individual outcomes. Full 
details on the GRADE and Cochrane Risk of Bias assessments are provided in the 
supplementary material. 
 
Results 
 
Study Selection 
The process of study selection is represented in the PRISMA diagram (see Figure 1). The 
titles and abstracts of 4676 papers were screened for eligibility. Of these, full-text reports 
were sought for 39. Three studies were not included because they were ongoing or could not 
be traced. A further 25 studies were excluded either because they did not report outcomes 
we could use (k=5), did not evaluate a treatment-related SDM intervention (k=11) were not 
randomised controlled trials (k=6), had an attrition rate of >50% (k=1), had <50% 
participants with non-affective psychosis (k=1) or were not published in English (k=1).  
 
A total of 11 RCTs were therefore included. Of these, four evaluated interventions designed 
to support SDM in relation to future treatment (ie., joint crisis planning or facilitated 
advance directives).(22-26) The remaining seven RCTs examined interventions designed to 
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support SDM in relation to current treatment. Of these, four examined the effects of paper 
(27, 28) or web-based (29, 30) decision or communication aids, one evaluated a group SDM 
intervention for service users (31), another evaluated the effects of training clinicians in an 
SDM approach to medicines management (32), and another RCT evaluated the effects of 
client-focused case management where treatment-related SDM was emphasised (33). 
Details of interventions delivered are provided in Table 2, alongside other study 
characteristics. Baseline demographics of participants are provided in Table DS1. 
 
Risk of bias and GRADE 
Table 1 provides a summary of the results for each outcome and the GRADE ratings of 
outcome quality. The detail of the Cochrane risk of bias ratings and a detailed rationale for 
all the ratings is provided in the supplementary material.  
 
Most (k=8) studies (22, 23, 26, 27, 29-33) had at least one judgement of unclear risk of 
selection bias. Risk of performance bias was high across all studies due to the nature of the 
interventions, which precluded blinding. Insufficient information in reporting also led to 
unclear detection bias in seven studies (22, 23, 26-28, 30, 31, 33), and one RCT stated no 
attempt to blind assessors was made (32). Risk of attrition bias was high or unclear on some 
post-intervention measures in just over half of the studies (k=6) (25-28, 32, 33). Risk of 
selective reporting bias was largely unclear, although there was an indication that three 
RCTs did not report all their outcomes (22, 26, 33). There was unclear risk of other sources 
of bias in four trials, namely risk of recruitment bias due to cluster randomised design (27, 
30, 32) and risk of cross-contamination due to in-patient research setting. (31) 
 
Outcomes (Table 1, Figures 2-5) 
 
Primary outcomes 
 
Indices of treatment-related empowerment (Figure 2) 
A small effect of SDM interventions on indices of subjective empowerment was observed 
(k=6, g=0.30, 95% CI 0.09, 0.51; low quality evidence). Six trials (25, 27, 29-31) involving 
a total of 843 participants provided data on this outcome. The quality of the evidence was 
downgraded due to its indirectness, with no study measuring subjective empowerment 
specifically, and imprecision, given that the 95% confidence interval included both trivial 
and moderate effects. There was, however, no evidence of undue heterogeneity (I2=35%). 
 
Two small studies (27, 31) provided follow-up data. One (27) did not find a significant 
effect at hospital discharge (g=0.16, CI -0.27, 0.60), but data was missing from >25% of 
participants. For the other, (31) ratings on an idiosyncratic measure of patient-perceived 
involvement were reported at 6-month follow-up, and suggested a large effect was 
maintained (g = 1.09, CI 0.49, 1.69). 
 
Risk of compulsory treatment (Figure 3) 
Data from three studies, (24-26) involving a total of 872 participants suggested a trend 
towards shared decision-making for future treatment (ie., crisis planning) reducing the 
likelihood of future compulsory inpatient treatment over the subsequent 15-18 months, but 
the estimate was imprecise and inconsistent and did not exclude the possibility of no effect 
(RR 0.59, 95% CI 0.35, 1.02, RD -0.10, 95% CI -0.19, 0; NNT 10, 95% CI 5, ∞). 
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Sensitivity analysis 
Excluding two studies (27, 33) with >25% missing data from the empowerment analysis 
resulted in a smaller effect size (k=4, g=0.17, 95% CI 0.01, 0.32), as did using a fixed-effect 
analysis instead of random-effects (k=8, g=0.23, 95% CI 0.09, 0.38).  
 
Secondary outcomes  
 
Relationship with clinician (Figure DS1) 
Overall, no significant effect of SDM interventions on patient or observer-rated relationship 
with clinician was found (k=8, g=0.14, 95% CI -0.05, 0.34). Eight studies with a total of 
1200 participants contributed to this outcome (23, 25, 26, 28, 29, 31-33). High heterogeneity 
(I2 60%) together with wide 95% confidence intervals (including both marginal negative 
effects and small positive effects) meant we rated the evidence as low quality. A moderate 
negative effect in Hamann 2011 (31) (g=-0.62, 95% CI -1.13, -0.11) contributed particularly 
to the high heterogeneity. This study of a group in-patient SDM intervention differed from 
the others in measuring ‘trust in physician’ rather than ‘alliance’ or ‘quality of 
communication’. Omitting this data suggested a small, statistically significant effect 
(g=0.21, 95% CI 0.07, 0.35; moderate quality evidence) favouring SDM, with a reduction in 
heterogeneity to 20%. 
 
Clinician-rated decision-making abilities (Figure DS2) 
Pooled data from three studies (22, 27, 31) involving a total of 520 participants, did not 
support the hypothesis that SDM interventions can enhance participant decision-making 
ability as rated by clinicians (k=3, g=0.27, 95% CI -0.24, 0.79, very low quality evidence). 
However heterogeneity was high (I2 = 83%), as was imprecision, with a 95% confidence 
interval including both small negative and large positive estimates, and only one of the 
studies (22) used a validated measure of decisional capacity.  
 
Sensitivity analyses 
Excluding four studies (25, 26, 32, 33) with >25% missing data from the analysis of service 
user-provider relationship reduced the overall effect size to 0.07 (-0.29, 0.42; k=4) but 
increased heterogeneity (I2 73%). Also removing the Hamann 2011 (31) study from this 
analysis increased the pooled effect size to 0.25 (0.08, 0.41; k=3) and reduced heterogeneity 
to 0%. Excluding one study (27) with >25% missing data from the analysis of decision-
making ability reduced the effect size to 0.02 (-0.60, 0.65) but did not reduce heterogeneity 
(I2 83%). 
 
Discussion 
 
Collaborative decision-making around psychiatric treatment, with greater consideration of 
patient preferences and values, may help service users with psychosis experience greater 
empowerment and reduced coercion in relation to their care. We examined whether and to 
what extent this hypothesis is supported by findings from clinical trials. Although we did 
not find any studies that measured treatment-related empowerment directly, our analysis of 
data from 6 RCTs (N=843) found that interventions which shared a focus on increasing 
SDM were associated with a small overall increase in indices of empowerment, including 
service users’ subjective sense of involvement in treatment, self-efficacy and autonomy. 
There was also trend-level evidence from 3 RCTs (N=872) that applying a shared decision-
making approach to decisions about future treatment may reduce by approximately 40% the 
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risk of service users experiencing compulsory care over a 15-18 month period, with a 
number needed to treat of approximately 10. Both primary outcomes were heavily 
influenced by the null results of a large multi-centre study,(25) however the ability of this 
trial to detect SDM-attributable benefits may have been compromised by what appeared to 
be poor implementation of SDM by participating clinicians (25, 34).  
 
What is the clinical significance of a standardised mean difference of 0.3? If we accept the 
results of the 2014 National Schizophrenia Audit (35), that 59% of service users diagnosed 
with schizophrenia in the UK do not feel involved in treatment decision-making, then the 
observed SDM effect size of 0.3 would translate to a number needed to treat of 9 (95% CI 6, 
26) (36). That is, SDM would need to be implemented with approximately 9 service users 
for 1 to experience greater empowerment. Given as many as 40-50% of clinicians do not 
regularly practice shared decision-making with service users with psychosis (35, 37), this is 
an important finding.  
 
We did not find clear evidence that SDM can improve treatment-related decision-making 
ability of service users, but the data were heterogeneous and imprecise. This is unfortunate, 
because impaired treatment decisional ability has been identified by clinicians as a barrier to 
implementation of shared decision-making in psychosis, and it may also increase the risk of 
involuntary treatment. We tried to examine the hypothesis that SDM might actually help 
increase decisional ability, however the very low quality of our findings prevented us from 
doing so. More rigorous studies investigating this question as a primary outcome would be 
welcome. 
 
Eight trials provided usable data on the effect of SDM on the service user-provider 
relationship, but the pooled results were also heterogeneous. A significant negative finding 
from Hamann et al (2011) (31) seemed to account for this, and excluding it resulted in an 
overall small positive finding for the remaining trials. Hamann et al used the Trust in 
Physician scale, (38) which conceptualises trust as agreement with statements such as “If my 
doctor tells me something is so, then it must be true.” It may be that SDM can cause small 
improvements in working alliance and communication, whilst also stimulating greater 
questioning of physician authority.  
 
Study limitations 
Our findings are limited by the absence of studies using direct measures of empowerment, 
and we were forced to consider more indirect indices of empowerment instead. We think the 
conceptual overlap of the different data we extracted is sufficient to ensure the pooled 
estimate is meaningful and interpretable. Nonetheless, our findings should be interpreted 
with caution and, if we wish to understand how to reduce disempowerment in 
schizophrenia, future RCTs need to use valid and reliable measures of this construct. SDM 
is often assessed by its ability to improve treatment satisfaction, but clearly this is not the 
same thing as empowerment, since empowerment might involve feeling able to express 
dissatisfaction. 
 
In interpreting our findings, it should also be noted that not all people diagnosed with 
schizophrenia wish to be involved in treatment decisions (6, 39). People who believe their 
decision-making ability is not good enough, or lack clear goals, may prefer to adopt a more 
passive role in their meetings with prescribers. We would argue that SDM should be 
implemented in a thoughtful way, and that clinical judgement and case formulation will 
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always be required when deciding what approach to take with particular service users. 
Coercing unwilling patients to engage with treatment decision-making may be as much a 
threat to their autonomy as excluding them without consultation. 
 
The interventions we included in our meta-analysis were varied. However they all shared a 
focus on increasing the use of SDM, and we assumed they were successful in this regard. 
Our interest lay not in finding out what interventions are best-placed to increase SDM, 
rather we wanted to find out whether doing so led to improvements in empowerment. Our 
assumption that interventions were successful in increasing SDM is challenged by the 
Thornicroft et al study, where the particular context may have moderated SDM uptake by 
clinicians (34). It could also be argued that our definition of SDM was overly broad, and 
that pooling results from trials of SDM and trials of joint crisis planning is misleading, since 
these interventions might have different aims. However we argue the only real distinction 
between these interventions is the timeframe of the decision to be made. Supporting this, the 
recent authors of the largest trial of joint crisis planning to date (25) have also described 
their approach as shared decision-making about future treatment (34).  
 
There was some evidence that excluding trials with >25% missing outcome data led to 
smaller estimates of benefit. We did not test whether the overall results were robust to 
making different assumptions about the outcomes of those who left early, but the overall 
rates of missing data were generally low and better than for other interventions in psychosis 
(40, 41). The limited number of studies for the primary outcome (k=6) also contributed to 
increased imprecision in our estimate. Although this is not uncommon for healthcare 
interventions – for example, the median number of trials in Cochrane reviews across 
medicine is six (42) - more trials are required to reduce uncertainty regarding the true effect. 
 
Finally, it may be argued that empowerment has value only in so far as it facilitates other 
established outcomes, such as symptom reduction, lower cost, or improved social outcomes. 
However there is considerable evidence that service users regard greater treatment-related 
empowerment not just as a means to some further end, but also as having value in its own 
right (13, 43, 44). Indeed, some 80% of people with experience of psychosis believe that 
knowing a great deal about treatment options is an essential part of what it means to 
experience recovery (13).  
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Table 1. Characteristis of included studies 
 
Trial Interventions Treatment setting Number randomised 
(n included in analysis) 
Included primary 
outcome (measure) 
Included secondary 
outcome (measure) 
Number and 
location of sites 
Hamann et al 
(2006)20 
Nurse- supported use of 
paper-based decision aid 
(30-60 minutes), preparing 
for consultation with doctor. 
Training for nurses and 
doctors involved. 
In-patient – acute 54  (Primary outcome: 30, 
secondary outcome: 36) 
 
Patient-perceived 
involvement (COMRADE) 
 
Clinician-rated 
decision-making 
abilities and knowledge 
(idiosyncratic measure) 
1 
Munich, Germany 
 Treatment as usual.  59 (Primary outcome: 45, 
secondary outcome: 52) 
   
Hamann et al 
(2011)57  
5-session group SDM 
intervention including 
motivational, behavioural 
and supportive elements. 
In-patient – post acute 
phase 
32 (32) Decision self-efficacy 
(DSS) 
 
 
Relationship with 
clinician (TPS) 
 
Clinician- rated 
decision- making 
abilities & knowledge 
(idiosyncratic measure 
of capacity) 
1 
Munich, Germany 
 5-session group cognitive 
training. 
 29 (29)    
Henderson et al 
(2004)52 
2-session shared facilitation 
of JCP, involving clinical 
team and possibly 
friend/advocate. 
Community with 
hospital admission in 
previous 2 years 
80 (80) Objective coercion (N 
admitted under MHA) 
None 7 CMHTs in 
South London and 1 
in Kent, England 
 Provision of written material 
about mental health services, 
MHA etc. 
 80 (80)    
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Trial Interventions Treatment setting Number randomised 
(n included in analysis) 
Included primary 
outcome (measure) 
Included secondary 
outcome (measure) 
Number and 
location of sites 
Steinwachs et al 
(2011)55 
Tailored web-based 
intervention (average 20 
minutes) to improve 
patients’ use of 
consultations. Includes 
medical and psychosocial 
areas of care, and modelling 
of targeted communication 
skills. 
Community & out-
patient 
Total for both groups: 56 
(24) 
Clinician-verbal dominance 
(ratio of clinician to patient 
statements) 
Relationship with 
clinician (greater 
clinician engagement - 
rated by observers) 
1 
Baltimore, USA 
 Video and written 
information about treatment 
for schizophrenia 
 Total for both groups: 56 
(26) 
   
Swanson et al 
(2006)51 
Elbogen et al 
(2007)50 
Research assistant- 
administered semi-structured 
interview, discussion and 
practical assistance to 
facilitate advance directive. 
Community 213 (Swanson:195 
Elbogen: 190) 
None Relationship with 
clinician (WAI) 
 
Clinician-rated 
decision-making ability 
(DCAT-PAD) 
1 
North Carolina, USA 
 Written information re 
advance directives and 
signposting 
 206 (Swanson:186 
Elbogen: 181) 
   
Thornicroft et al 
(2013)53 
2-meeting joint facilitation 
of JCP. Facilitated by senior 
nurse. Involved clinical team 
and possibly family/friend.  
Community 285 
(MPCS: 213, Admission: 
267, WAI: 106) 
Perceived coercion (MPCS) 
 
Objective coercion (N 
admitted under MHA) 
Relationship with 
clinician (WAI) 
3 sites across 
England: 
Birmingham  
 
Manchester and  
Lancashire  
 
South London 
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Trial Interventions Treatment setting Number randomised 
(n included in analysis) 
Included primary 
outcome (measure) 
Included secondary 
outcome (measure) 
Number and 
location of sites 
 Treatment as usual under 
CPA 
 284  
(MPCS: 245,  Admission: 
280, WAI: 240) 
   
Van Os et al  
(2004)54 
Use of problem checklist 
with brief guidance, 
covering medical, 
psychological/ 
emotional and psychosocial 
areas, prior to consultation 
with doctor to enhance 
communication. 
Community 67 (NS) None Relationship with 
clinician 
(4-point rating on single 
question measuring 
quality of patient-
clinician 
communication) 
7 centres across 
Europe: Maastricht 
Oviedo, Gijon 
Hamburg, Copen-
hagen, 
Milan, Nice 
 Treatment as usual  67 (NS)    
Woltmann et al 
(2011)56 
Electronic decision support 
system to facilitate 
synthesising perspectives in 
care planning for patients 
and case managers. 
Community 40 (40) 
 
Patient-perceived 
involvement (idiosyncratic 
measure) 
None 1 
Dartmouth, USA 
 Care planning as usual.  40 (40)    
Ruchlewska et al 
(2015) 
Clinician-facilitated crisis 
plan 
Community 70  
(46 and 50 provided WAI 
data at 9 and 18 months) 
Objective coercion (N 
admitted under court order) 
Relationship with 
clinician (WAI) 
12 Assertive 
Community Teams 
and 
Illness Management 
& Recovery Teams 
in Rotterdam, 
Netherlands 
 Patient advocate-facilitated 
crisis plan 
 69  
(57 and 50 provided WAI 
data at 9 and 18 months) 
   
17 
 
Trial Interventions Treatment setting Number randomised 
(n included in analysis) 
Included primary 
outcome (measure) 
Included secondary 
outcome (measure) 
Number and 
location of sites 
 Usual care  73  
(50 and 52 provided WAI 
data at 9 and 18 months) 
   
O’Donnell et al 1999  Client-focused case 
management (strong SDM 
focus) 
Community 39  
(~32 provided data at 12 
months) 
Patient-perceived 
involvement (N agreeing 
they ‘had more say’ on 
idiosyncratic measure) 
Relationship with 
clinician (N reporting 
satisfaction with care 
manager on 
idiosyncratic measure) 
1  
Sydney, Australia  
 Client-focused case 
management plus peer 
advocacy (strong SDM 
focus) 
 45  
(~27 provided data at 12 
months) 
   
 Standard community case 
management 
 35  
(~20 provided data at 12 
months) 
   
Harris et al 2009 Medication management 
training (strong SDM focus)  
Community 88 (72) None Relationship with 
clinician (working 
alliance) 
1, Manchester, 
England 
 Waiting list for medication 
management training 
 81 (51) None   
 
Note: COMRADE, Combined Outcome Measure for Risk Communication and Treatment Decision Making Effectiveness;78 DSS, Decision Self-
efficacy Scale;79 TPS, Trust in Physician Scale;60 JCP, Joint Crisis Plan; MPCS, MacArthur Perceived Coercion Scale;81 CPA, Care Plan 
Approach; MHA, Mental Health Act; CMHT, Community Mental health Team; NS, not specified; NS*, not specified – no significant difference 
between groups; RIAS, Roter Interaction Analysis System;82 WAI, Working Alliance Inventory;83 DCAT-PAD, Decisional Competence 
Assessment Tool for Psychiatric Advance Directives.84  
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Table 2   Summary of results 
 
Outcome 
(Number of trials) 
Number of 
participants: 
intervention 
(I), control (C) 
 
Effect size (s) (95% 
CI) 
Heterogeneity (I2) 
and p- value 
GRADE quality 
rating 
Indices of 
subjective 
empowerment 
(k=6) 
843  
(I: 423, C: 420) 
g = 0.30 (0.09, 0.51) 
  
I2 = 35%, p = .17 Low 
Risk of compulsory 
treatment (k=3) 
872  
(I: 435, C: 437) 
RR = 0.59 (0.35, 1.02) 
RD = -0.10 (-0.19, 0) 
NNT = 10 (5, ∞) 
 
I2 = 61%, p =.08 Low 
Relationship with 
clinician (k=8) 
1261  
(I: 577, C: 684) 
g = 0.14 (-0.05, 0.34) I2 = 60%, p = .02 Low 
Relationship with 
clinician, excluding 
Hamann et al 
(2011) (k=7) 
1200  
(I: 545, C: 655) 
g = 0.21 (0.07, 0.35) I2 = 20%, p = .27 Moderate 
Clinician-rated 
decision-making 
abilities and 
knowledge (k=3) 
520  
(I: 258, C: 262) 
g = 0.27 (-0.24, 0.79) I2 = 83% p = 0.003 Very low 
 
19 
 
Figure 1. PRISMA flowchart showing process of study selection 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of irrelevant or 
duplicate records 
excluded on basis of title 
or abstract: 4638 
Number of full-text 
reports screened for 
eligibility: 39 
Number of RCTs 
included in review: 11 
 
Number of studies 
excluded: 28     
 
Ongoing studies: 2              
Untraced reports: 1 
No usable outcomes: 5 Not 
treatment SDM: 11                   
Not RCT: 6                         
>50% data missing: 1 
>50% participants with 
psychotic disorder: 1                                                          
Non-English: 1 
 
Number of records 
identified through 
database searching: 
4665  
Number or records 
identified through 
other sources: 11 
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Figure 2: The effect of shared decision-making on indices of subjective empowerment 
  
 
 
 
Study Outcome N 
SDM 
N 
Control 
N 
Total 
  g 
(95% CI) 
% 
Weight 
Hamann 2006 Perceived involvement 30 45 75   0.50 (0.03, 0.96) 14.31 
Hamann 2011 Decision self-efficacy 32 29 61   0.04 (-0.45, 0.54) 13.02 
Steinwachs 2011 Reduced clinician verbal dominance 24 26 50   0.60 (0.04, 1.16) 10.93 
Thornicroft 2013 Reduced perceived coercion 213 245 458   0.13 (-0.05, 0.32) 35.56 
Woltmann 2011 Perceived involvement 40 40 80   0.18 (-0.26, 0.62) 15.67 
O’Donnell 1999 ‘have more say’ 84 35 119   0.74 (0.17, 1.31) 10.52 
         
 Total 423 420 843   0.30 (0.09, 0.51) 100.00 
 Q=7.70, p=0.17, I2=35%        
 
Empowerment2
ES
10
Study 
Hamann 2011, decision self-efficacy 
Thornicroft 2013, perceived coercion 
Woltmann 2 11, perceived involvement 
Overall 
Q=7.70, p=0.17, I2=35%
Hamann 2006, perceived involvement 
Steinwachs 2011, reduced clinician verbal dominance 
O'Donnell 1999, 'have more say' 
    ES (95% CI)          % Weight
   0.04  ( -0.45,  0.54)     13.02
   0.   .05,  0.32)     35.56
   0.   .26,  0.62)     15.67
   0.    0. ,  0.51)    100.00
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control                           SDM 
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Figure 3: The effect of shared decision-making on risk of compulsory treatment 
 
 
 
  
 
Study Outcome N Cases /  
N SDM 
N Cases /  
N Control 
N Total   RR 
(95% CI) 
% 
Weight 
Henderson 2004 Admission, MHA 10/80 21/80 160   0.48 (0.34, 0.96) 29.37 
Thornicroft 2013 Admission, MHA 49/285 56/284 569   0.87 (0.62, 1.23) 45.65 
Ruchlewska 2015 Admission, Court Order 7/70 19/73 143   0.38 (0.17, 0.86) 24.99 
         
 Total 66/435 96/437 872   0.59 (0.36, 1.02) 100.00 
 Q=4.90, p=0.09, I2=59%        
 RR
1
Study 
Ruchlewska 2015 
Henderson 2004 
Overall 
Q=4.90, p=0.09, I2=59%
Thornicroft 2013
    RR (95% CI)          % Weight
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   0.87  (  0.62,  1.23)     45.65
              RR           1 
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